Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00970073 · ClinicalTrials.gov registry record · NA
Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00970073 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 30 participants.
The verdict
NCT00970073, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will evaluate the use of a drug called Thymoglobulin, combined with a delayed start of the anti-rejection drugs (10 days after liver transplant), compared to the current approach of starting anti-rejection drugs called calcineurin inhibitors or CNI's within 2 days after the liver transplant.
Interventions
- DRUG Mycophenolate mofetil
- BIOLOGICAL Thymoglobulin 3mg total
- BIOLOGICAL Thymoglobulin 4.5mg total
- DRUG tacrolimus 3-8
- DRUG tacrolimus 8-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-08 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00970073
The ClinicalTrials.gov registry entry for NCT00970073 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Mycophenolate mofetil is the first listed.
NCT00970073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00970073 about?
NCT00970073 is a clinical study titled "Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant". This study will evaluate the use of a drug called Thymoglobulin, combined with a delayed start of the anti-rejection drugs (10 days after liver transplant), compared to the current approach of starting anti-rejection drugs called calcineurin inhibitors or CNI's within 2 days after the liver transpla...
What is the current status of trial NCT00970073?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2009-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00970073?
The interventions under investigation include: Mycophenolate mofetil (DRUG), Thymoglobulin 3mg total (BIOLOGICAL), Thymoglobulin 4.5mg total (BIOLOGICAL), tacrolimus 3-8 (DRUG), tacrolimus 8-12 (DRUG).
Who is sponsoring clinical trial NCT00970073?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.